Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers

This is a Phase 1, randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, tolerability, and pharmacokinetics of ZT003 following subcutaneous administration in healthy adult participants. The study includes both single ascending dose (SAD) and multiple ascending dose (MAD) parts.

NCT Number	NCT07184502
Lead Sponsor	Beijing QL Biopharmaceutical Co.,Ltd
Conditions	Healthy
Enrollment	72 participants
Start Date	2025-10-16
Primary Completion	2026-12-24 (estimated)
Study Completion	2027-04-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-27